Anke Biotechnology: Joint venture company PA3-17 Injection approved to enter crucial Phase II clinical trial.

Anke Biology announced that its equity-invested companies BoShengJi Medical Technology Co., Ltd. and BoShengJi Anke Cell Technology Co., Ltd. have received the meeting minutes of the Phase II communication meeting for PA3-17 injection issued by the Drug Evaluation Center of the National Medical Products Administration, agreeing to the applicant to conduct key Phase II clinical trials of PA3-17 injection. PA3-17 injection is the world's first autologous CAR-T cell therapy product targeting CD7 developed by BoShengJi Anke, which has obtained approval for new drug clinical trials, and is used to treat adult relapsed, refractory CD7-positive hematologic malignancies.